Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P50CA084724 | U.S. NIH Grant/Contract | View source | |
| P50DA019706 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to determine if bupropion plus counseling was more effective than bupropion alone or counseling alone in helping smokers quit smoking.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active bupropion + counseling | Active Comparator | Active bupropion SR plus eight 10-minute individual counseling sessions. |
|
| Active bupropion , No counseling | Active Comparator | Active bupropion, No counseling, only medication checks |
|
| Placebo medication + counseling | Placebo Comparator | Placebo bupropion plus eight 10-minute individual counseling sessions |
|
| Placebo medication, No counseling | Placebo Comparator | Placebo bupropion, No counseling, just medication checks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active bupropion + counseling | Drug | Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks. Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date. |
| Measure | Description | Time Frame |
|---|---|---|
| 7-day Point Prevalence Abstinence From Smoking at 6 Months | No smoking, not even a puff, during the 7 days prior to the 6 month follow-up. Biochemically confirmed. | 6 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Timothy B Baker, PhD | University of Wisconsin, Madison | Principal Investigator |
| Timothy B Baker, PhD | University of Wisconsin, Madison | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UW Center for Tobacco Research and Intervention | Madison | Wisconsin | 53711 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18418793 | Result | McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, Baker TB. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res. 2008 Apr;10(4):717-29. doi: 10.1080/14622200801968343. | |
| 37230961 | Derived | Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023 May 24;5(5):CD000031. doi: 10.1002/14651858.CD000031.pub6. |
Not provided
Not provided
Participants were 1) phone screened, 2) invited to group orientation where signed consent was obtained, and 3) completed CO testing and office visit for physical exam. Participants were considered enrolled after passing all 3 steps and randomization occurred at enrollment.
Participants recruited from Madison, WI area through TV, radio, newspaper advertisements from January, 2001 to October 2002
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Active Bupropion + Counseling | Active bupropion SR plus eight 10-minute individual counseling sessions. |
| FG001 | Active Bupropion , No Counseling | Active bupropion, No counseling, only medication checks |
| FG002 | Placebo Medication + Counseling | Placebo bupropion plus eight 10-minute individual counseling sessions |
| FG003 | Placebo Medication, No Counseling | Placebo bupropion, No counseling, just medication checks |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Active Bupropion + Counseling | Active bupropion SR plus eight 10-minute individual counseling sessions. |
| BG001 | Active Bupropion , No Counseling | Active bupropion, No counseling, only medication checks |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | 7-day Point Prevalence Abstinence From Smoking at 6 Months | No smoking, not even a puff, during the 7 days prior to the 6 month follow-up. Biochemically confirmed. | Full intent-to-treat sample | Posted | Number | Number of abstinent participants | 6 months |
|
6 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo Medication | Medications: Pre-quit - one placebo pill for 3 days before quit day, then one placebo pill twice a day 4 days before quit day for 8 weeks after the quit date. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| upper respiratory infection | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
Lack of a no-treatment control condition; limited ability to generalize to broader population
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Timothy Baker, PhD, Director of Research | University of Wisconsin Center for Tobacco Research and Intervention | (608) 262-7568 | tbb@ctri.wisc.edu |
Not provided
| ID | Term |
|---|---|
| D014029 | Tobacco Use Disorder |
| D012907 | Smoking |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D003376 | Counseling |
| ID | Term |
|---|---|
| D008605 | Mental Health Services |
| D004191 | Behavioral Disciplines and Activities |
| D003153 | Community Health Services |
| D006296 | Health Services |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Active bupropion, No counseling | Drug | Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day. Counseling: No cessation counseling, only medication checks |
|
| Placebo medication + counseling | Drug | Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day. Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day. |
|
| Placebo medication, No counseling | Drug | Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day. Counseling: No counseling, just medication checks |
|
| BG002 | Placebo Medication + Counseling | Placebo bupropion plus eight 10-minute individual counseling sessions |
| BG003 | Placebo Medication, No Counseling | Placebo bupropion, No counseling, just medication checks |
| BG004 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| 7-day point prevalence abstinence | Participants provided breath samples for carbon monoxide(CO)testing at all visits and provided a blood sample to assess cotinine (the first metabolite of nicotine)levels at baseline and again at end of treatment. | Number | participants |
|
Active bupropion, No counseling: Medications: Medications: Pre-quit - 150mg bupropion SR per day 3 days before quit day, then 150mg twice a day 4 days before quit day; 150mg bupropion SR twice daily for 8 weeks after the quit date. No cessation counseling, medication management and assessment only.
| OG002 | Placebo + Counseling | : Medications: Pre-quit - Placebo bupropion one per day 3 days before quit day, then two per day 4 days before quit day; placebo bupropion twice daily for 8 weeks after the quit date. Counseling: Pre-quit - Two 10-minute sessions; Post-quit: Eight weekly 10-minute sessions |
| OG003 | Placebo, No Counseling | : Medications: Pre-quit - Placebo bupropion one per day 3 days before quit day, then two per day 4 days before quit day; placebo bupropion twice daily for 8 weeks after the quit date. No cessation counseling, medication management and assessment only. |
|
|
|
| 0 |
| 234 |
| 66 |
| 234 |
| EG001 | Active Medication | Pre-quit - 150mg bupropion SR per day 3 days before quit day, then 150mg twice a day 4 days before quit day; 150mg bupropion SR twice daily for 8 weeks after the quit date. | 0 | 229 | 94 | 229 |
| depression | Nervous system disorders | Non-systematic Assessment |
|
| insomnia | Nervous system disorders | Non-systematic Assessment |
|
| Headache | Nervous system disorders | Non-systematic Assessment |
|
| Feeling jittery | Psychiatric disorders | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D005159 | Health Care Facilities Workforce and Services |